4.7 Article

Rapid susceptibility profiling of carbapenem-resistant Klebsiella pneumoniae

Journal

SCIENTIFIC REPORTS
Volume 7, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41598-017-02009-3

Keywords

-

Funding

  1. Health Department of Western Australia [RTP 9]
  2. Bill and Melinda Gates Foundation (Gates Foundation Grand Challenges) [OPP 1150984]
  3. Accelerate Diagnostics
  4. Achaogen Inc.
  5. Allecra Therapeutics
  6. Amplex
  7. AstraZeneca UK Ltd.
  8. Basilea Pharmaceutica
  9. Becton Dickinson Diagnostics
  10. BioMerieux
  11. Bio-Rad Laboratories
  12. BSAC
  13. Cepheid
  14. Check-Points B.V.
  15. Cubist Pharmaceuticals
  16. Department of Health
  17. Enigma Diagnostics
  18. Food Standards Agency
  19. GlaxoSmithKline Services Ltd.
  20. Henry Stewart Talks
  21. IHMA Ltd.
  22. Kalidex Pharmaceuticals
  23. Melinta Therapeutics
  24. Merck Sharpe Dohme Corp
  25. Meiji Seika Pharma Co
  26. Mobidiag
  27. Momentum Biosciences Ltd.
  28. Nordic Pharma Ltd.
  29. Norgine Pharmaceuticals
  30. Rempex Pharmaceuticals Ltd.
  31. Roche
  32. Rokitan Ltd.
  33. Smith Nephew UK Ltd.
  34. Trius Therapeutics
  35. VenatoRx Pharmaceuticals and Wockhardt Ltd.
  36. University Government
  37. State Government
  38. Commonwealth Government
  39. Bill & Melinda Gates Foundation - Grand Challenges Explorations Initiative [OPP1150984] Funding Source: researchfish
  40. Bill and Melinda Gates Foundation [OPP1150984] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

The expanding global distribution of multi-resistant Klebsiella pneumoniae demands faster antimicrobial susceptibility testing (AST) to guide antibiotic treatment. Current ASTs rely on time-consuming differentiation of resistance and susceptibility after initial isolation of bacteria from a clinical specimen. Here we describe a flow cytometry workflow to determine carbapenem susceptibility from bacterial cell characteristics in an international K. pneumoniae isolate collection (n = 48), with a range of carbapenemases. Our flow cytometry-assisted susceptibility test (FAST) method combines rapid qualitative susceptible/non-susceptible classification and quantitative MIC measurement in a single process completed shortly after receipt of a primary isolate (54 and 158 minutes respectively). The qualitative FAST results and FAST-derived MIC (MICFAST) correspond closely with broth microdilution MIC (MICBMD, Matthew's correlation coefficient 0.887), align with the international AST standard (ISO 200776-1; 2006) and could be used for rapid determination of antimicrobial susceptibility in a wider range of Gram negative and Gram positive bacteria.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available